European Commission approves Merck’s Keytruda as part of a treatment regimen for adults with resectable LA-HNSCC ...
Merck, known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as monotherapy for the treatment of resectable locally advanced head and neck …